MIAMI, Aug. 25, 2022 Longeveron Inc. , a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that. | August 25, 2022
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a. | June 28, 2022
24.03.2022 - -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -Reported positive preclinical data at SITC demonstrating the potential to drive targeted .